Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance.

In this pilot clinical trial, we evaluated rates of residual replication in persons without lamivudine resistance-associated mutations in proviral DNA population sequencing who switched to dolutegravir plus lamivudine. After 144 weeks, there was no signal of changes in residual viremia based on qualitative detection methods, irrespective of past lamivudine resistance. Clinical Trials Registration. NCT03539224.

Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study).

BACKGROUND: Previously selected lamivudine resistance-associated mutations (RAMs) may remain archived within the proviral HIV-DNA. OBJECTIVES: To evaluate the ability of proviral DNA genotyping to detect lamivudine RAMs in HIV-1 virologically suppressed participants; the correlation between Sanger and next generation sequencing (NGS); and predictive factors for detection of lamivudine RAMs in proviral DNA. METHODS: Cross-sectional study of participants on stable antiretroviral therapy and suppressed for ≥1 year. Analysis of proviral DNA was performed by Sanger sequencing in whole blood and by NGS in PBMCs. RESULTS: We analysed samples from 102 subjects (52 with and 50 without lamivudine RAMs in historical plasma RNA-genotypes). Among participants with previous lamivudine resistance, Sanger sequencing detected RAMs in 26.9%. Detection rates significantly increased using NGS: 47.9%, 64.6%, 75% and 87.5% with the 20%, 10%, 5% and 1% thresholds, respectively. As for participants without historical lamivudine resistance, Sanger detected the RAMs in 1/49 (2%), and NGS (5% threshold) in 8/45 (17.8%). Multivariate models fitted to the whole population revealed that having a history of lamivudine resistance was a risk factor for detection of lamivudine RAMs by NGS. Among participants with historical lamivudine resistance, multivariate analysis showed that a longer time since HIV diagnosis was associated with persistence of archived mutations by NGS at thresholds of >10% [OR 1.10 (95% CI: 1.00-1.24)] and >5% [OR 1.16 (95% CI: 1.02-1.32)]. CONCLUSIONS: Proviral DNA Sanger sequencing does not detect the majority of historical lamivudine RAMs. NGS increases the sensitivity of detection at lower thresholds, although the relevance of these minority populations with lamivudine RAMs needs further evaluation.

Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.

BACKGROUND: In the ART-PRO pilot trial there were no virological failures through 48 weeks of treatment with dolutegravir plus lamivudine in suppressed individuals with and without archived lamivudine resistance-associated mutations (RAMs) detected through next-generation sequencing (NGS) but without evidence of lamivudine RAMs in baseline proviral DNA population sequencing. OBJECTIVES: To present 96 week results from ART-PRO. METHODS: Open-label, single-arm pilot trial. At baseline, all participants switched to dolutegravir plus lamivudine. Participants were excluded if proviral DNA population genotyping detected lamivudine RAMs. To detect resistance minority variants, proviral DNA NGS was retrospectively performed from baseline samples. For this analysis the efficacy endpoint was the proportion of participants with <50 HIV-1 RNA copies/mL at week 96. Safety and tolerability outcomes were incidence of adverse events and treatment discontinuations. RESULTS: Forty-one participants were included, 21 with lamivudine RAMs in historical plasma RNA genotypes. Baseline proviral DNA NGS detected lamivudine RAMs (M184V/I and/or K65R/E/N) above a 5% threshold in 71.4% (15/21) and 15% (3/20) of participants with and without history of lamivudine resistance, respectively. At 96 weeks, 90.2% of participants achieved the efficacy endpoint. Between week 48 and 96 there was one discontinuation due to consent withdrawal and no discontinuations related to adverse events. Two participants had a transient viral rebound, both re-suppressed on dolutegravir plus lamivudine. Through week 96, there were no virological failures. CONCLUSIONS: In this pilot trial, dolutegravir plus lamivudine maintained virological suppression at 96 weeks despite historical lamivudine resistance and persisting archived minority lamivudine RAMs.

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).

BACKGROUND: We investigated the efficacy of a switch to dolutegravir plus lamivudine in aviremic individuals without evidence of persistent lamivudine resistance-associated mutations in baseline proviral DNA population sequencing. METHODS: Open-label, single-arm, 48-week pilot trial. HIV-1 infected adults, naïve to integrase inhibitors, with CD4+ above 350 cell/µL and fewer than 50 HIV-1 RNA copies per mL the year prior to study entry switched to dolutegravir plus lamivudine. Participants were excluded if baseline proviral DNA population genotyping detected lamivudine resistance-associated mutations. To detect resistance minority variants, proviral DNA next-generation sequencing was retrospectively performed from baseline samples. Primary efficacy endpoint was proportion of participants with fewer than 50 HIV-1 RNA copies per mL at week 48. Safety and tolerability outcomes were incidence of adverse events and treatment discontinuations. ART-PRO is registered with ClinicalTrials.gov, NCT03539224. FINDINGS: 41 participants switched to dolutegravir plus lamivudine, 21 with lamivudine resistance mutations in historical plasma genotypes. Baseline next-generation sequencing detected lamivudine resistance mutations (M184V/I and/or K65R/E/N) over a 5% threshold in 15/21 (71·4%) and 3/20 (15%) of participants with and without history of lamivudine resistance, respectively. At week 48, 92·7% of participants (38/41) had fewer than 50 HIV-1 RNA copies per mL. There were no cases of virologic failure. Three participants with historical lamivudine resistance were prematurely discontinued from the study (2 protocol violations, one adverse event). Ten participants (4 in the group with historical lamivudine resistance) had a transient viral rebound, all resuppressed on dolutegravir plus lamivudine. There were 28 drug-related adverse events, only one leading to discontinuation. INTERPRETATION: In this pilot trial, dolutegravir plus lamivudine was effective in maintaining virologic control despite past historical lamivudine resistance and presence of archived lamivudine resistance-associated mutations detected by next generation sequencing. Further studies are needed to confirm our results. FUNDING: Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III PI16/00837-PI16/00678.

[Relationship between hepatic fibrosis measured by transient elastography and peripheral blood CD4+ lymphocyte values]. / Relación entre fibrosis hepática medida por elastografía transitoria y valores de linfocitos CD4+ en sangre periférica.

Advanced hepatic fibrosis decreases absolute CD41 lymphocyte count in HIV-infected patients. The correlation between hepatic stiffness measured by transient elastography and absolute CD41 lymphocyte count is unknown. Analysis of the correlation between transient elastography parameters and absolute CD41 lymphocyte count in 223 HIV-infected patients with chronic viral hepatitis. As compared to patients without significant fibrosis, absolute CD41 cell count was lower in patients with significant hepatic fibrosis (384 cel/microL vs. 431 cel/microL; P = 0.023) and in patients with advanced hepatic fibrosis (330 cel/microL vs. 431 cel/microL; P = 0.002). There is a significant association between hepatic stiffness measured by transient elastography and absolute CD41 lymphocyte count in HIV-infected patients with chronic viral hepatitis.

Relación entre fibrosis hepática medida por elastografía transitoria y valores de linfocitos CD4+ en sangre periférica / Relationship between hepatic fibrosis measured by transient elastography and peripheral blood CD4+ lymphocyte values

La fibrosis hepática avanzada disminuye la cifra absoluta de linfocitos CD4+ en pacientes con infección por el virus de la inmunodeficiencia humana (VIH). Se desconoce si existe una correlación entre rigidez hepática medida por elastografía transitoria y la cifra absoluta de linfocitosCD4+.Se realiza análisis de la correlación entre resultados de elastografía transitoria y cifras de linfocitos CD4+ en223 sujetos coinfectados por VIH y virus hepatotropos. Los valores absolutos de linfocitos CD4+ fueron menores en pacientes con fibrosis significativa (384 céls./ml frentea 431 céls./ml; p = 0,023) y en pacientes con fibrosisavanzada (330 céls./ml frente a 431 céls./ml; p = 0,002).Existe una asociación significativa entre la fibrosishepática medida por elastografía transitoria y los valores absolutos de linfocitos CD4+ en pacientes coinfectados por VIH y virus hepatotropos (AU)

Advanced hepatic fibrosis decreases absoluteCD4+ lymphocyte count in HIV-infected patients. The correlation between hepatic stiffness measured by transient elastography and absolute CD4+ lymphocytecount is unknown. Analysis of the correlation between transient elastography parameters and absolute CD4+ lymphocyte count in223 HIV-infected patients with chronic viral hepatitis. As compared to patients without significant fibrosis, absolute CD4+ cell count was lower in patients with significant hepatic fibrosis (384 cel/mL vs. 431 cel/mL;P = 0.023) and in patients with advanced hepatic fibrosis(330 cel/mL vs. 431 cel/mL; P = 0.002). There is a significant association between hepatic stiffness measured by transient elastography and absoluteCD4 lymphocyte count in HIV-infected patients with chronic viral hepatitis (AU)